Treatment of relapsed and refractory acute myelogenous leukemia

Leukemia

Volumn 14, Issue 3, 2000, Pages 476-479

  Estey, E H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AML; Salvage therapy

Indexed keywords

7 HYDROXYSTAUROSPORINE; 9 AMINOCAMPTOTHECIN; ANNAMYCIN; ANTINEOPLASTIC AGENT; BCH; BORTEZOMIB; CARBOPLATIN; CD33 ANTIGEN; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTIDINE DERIVATIVE; DEOXYAZACYTIDINE; DEXAMETHASONE; DOLASTATIN; DOXORUBICIN; ETOPOSIDE; EXATECAN; FLUDARABINE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; MERBARONE; MONOCLONAL ANTIBODY; PACLITAXEL; SEBRIPLATIN; SU 516; TALLIMUSTINE; THALIDOMIDE; TOPOTECAN; TRIMETREXATE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; CLINICAL PROTOCOL; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY;

EID: 0034009065     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401568     Document Type: Conference Paper

References (12)

1. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4: 184-188.
2. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood 1996; 88: 756.
3. Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei E III. The effect of chemotherapy on acute leukemia in the human. J Chron Dis 1961; 14: 593.
4. Estey E, Shen Y, Thall PF. Effect of time to achieve CR on subsequent survival time and disease-free survival time in patients with AML, RAEB-t, or RAEB in whom response is established alter the first course of chemotherapy. Blood (in press).
5. Vey N, Keating M, Giles F, Cortes J, Beran M, Estey E. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy. Blood 1999; 93: 3149-3150.
6. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
7. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14: 1149-1161.
8. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 1998; 54: 251-264.
9. Thall PF, Estey EH, Sung His-Guang. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Invest New Drugs (in press).
10. Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995; 14: 357-379.
11. Thall PF, Sung HG. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998; 17: 1563-1580.
12. Thall PF, Estey EH. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. Stat Med 1993; 12: 1197-1211.